» Articles » PMID: 26938675

CD163(+) M2-type Tumor-associated Macrophage Support the Suppression of Tumor-infiltrating T Cells in Osteosarcoma

Overview
Date 2016 Mar 4
PMID 26938675
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma is one of the most common childhood cancers with high numbers of cancer-related deaths. Progress in conventional therapies is showing limited improvement. An adaptive T cell-based immunotherapy represents a promising new therapeutic option, but to improve its efficacy, regulatory mechanisms in osteosarcoma need further elucidation. Here, to evaluate the regulatory effect of tumor microenvironment of T cells in osteosarcoma, we examined the peripheral blood (PB) and tumor infiltrating (TI) T cells, and their correlations with PB and tumor immune characteristics. We found that TI T cells contained significantly higher levels of TIM-3(+)PD-1(-) and TIM-3(+)PD-1(+) cells than their PB counterparts. Similar to that in chronic HIV and HCV infections, these TIM-3(+)PD-1(-) and TIM-3(+)PD-1(+) T cells presented reduced proliferation and proinflammatory cytokine secretion in response to stimulation. Presence of M2-type (CD163(+)) macrophages exacerbated T cell immunosuppression, since frequencies of CD163(+) tumor-associated macrophages were directly correlated with the frequencies of suppressed TIM-3(+)PD-1(+) T cells. Moreover, depletion of CD163(+) macrophages significantly improved T cell proliferation and proinflammatory cytokine production. Overall, our data presented an intratumoral T cell-specific immunosuppression that was amplified by M2-type tumor-associated macrophages.

Citing Articles

Harnessing myeloid cells in cancer.

Park S, Pylaeva E, Bhuria V, Gambardella A, Schiavoni G, Mougiakakos D Mol Cancer. 2025; 24(1):69.

PMID: 40050933 PMC: 11887392. DOI: 10.1186/s12943-025-02249-2.


A telomere-related signature for predicting prognosis and assessing immune microenvironment in osteosarcoma.

Li S, Zhang L, Zhang H Front Pharmacol. 2025; 15:1532610.

PMID: 39980969 PMC: 11841432. DOI: 10.3389/fphar.2024.1532610.


Immunotherapy of osteosarcoma based on immune microenvironment modulation.

Lian H, Zhang J, Hou S, Ma S, Yu J, Zhao W Front Immunol. 2025; 15:1498060.

PMID: 39916962 PMC: 11799554. DOI: 10.3389/fimmu.2024.1498060.


Tumor-associated-fibrosis and active collagen-CD44 axis characterize a poor-prognosis subtype of gastric cancer and contribute to tumor immunosuppression.

Yang Y, Sun H, Yu H, Wang L, Gao C, Mei H J Transl Med. 2025; 23(1):123.

PMID: 39871345 PMC: 11773867. DOI: 10.1186/s12967-025-06070-9.


AXL: shapers of tumor progression and immunosuppressive microenvironments.

Liu Y, Xu L, Dou Y, He Y Mol Cancer. 2025; 24(1):11.

PMID: 39799359 PMC: 11724481. DOI: 10.1186/s12943-024-02210-9.